Search Results - "ADES, Lionel"

Eprenetapopt Plus Azacitidine in TP53 -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) by Cluzeau, Thomas, Sebert, Marie, Rahmé, Ramy, Cuzzubbo, Stefania, Lehmann-Che, Jacqueline, Madelaine, Isabelle, Peterlin, Pierre, Bève, Blandine, Attalah, Habiba, Chermat, Fatiha, Miekoutima, Elsa, Rauzy, Odile Beyne, Recher, Christian, Stamatoullas, Aspasia, Willems, Lise, Raffoux, Emmanuel, Berthon, Céline, Quesnel, Bruno, Loschi, Michael, Carpentier, Antoine F, Sallman, David A, Komrokji, Rami, Walter-Petrich, Anouk, Chevret, Sylvie, Ades, Lionel, Fenaux, Pierre

“…-mutated ( ) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40%…”
Get full text

Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells by El Hajj, Hiba, Dassouki, Zeina, Berthier, Caroline, Raffoux, Emmanuel, Ades, Lionel, Legrand, Olivier, Hleihel, Rita, Sahin, Umut, Tawil, Nadim, Salameh, Ala, Zibara, Kazem, Darwiche, Nadine, Mohty, Mohamad, Dombret, Hervé, Fenaux, Pierre, de Thé, Hugues, Bazarbachi, Ali

“…Nucleophosmin-1 (NPM1) is the most frequently mutated gene in acute myeloid leukemia (AML). Addition of retinoic acid (RA) to chemotherapy was proposed to…”
Get full text

Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis by KORETH, John, PIDALA, Joseph, FENAUX, Pierre, JADERSTEN, Martin, HELLSTROM-LINDBERG, Eva, GALE, Robert Peter, BEACH, C. L, LEE, Stephanie J, HOROWITZ, Mary M, GREENBERG, Peter L, TALLMAN, Martin S, DIPERSIO, John F, PEREZ, Waleska S, BUNJES, Donald, WEISDORF, Daniel J, CUTLER, Corey, DEEG, H. Joachim, GARCIA-MANERO, Guillermo, MALCOVATI, Luca, CAZZOLA, Mario, PARK, Sophie, ITZYKSON, Raphael, ADES, Lionel

“…Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are more common in patients aged ≥ 60 years and are incurable with conventional…”
Get full text

Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies by DAMAJ, Gandhi, DUHAMEL, Alain, BULABOIS, Claude-Eric, HUYNH, Anne, BAY, Jacques-Olivier, LEGRAND, Faeyzeh, DECONINCK, Eric, FEGUEUX, Nathalie, CLEMENT, Laurence, DAURIAC, Charles, MAILLARD, Natacha, CORNILLON, Jérôme, ROBIN, Marie, ADES, Lionel, GUILLERM, Gaelle, SCHMIDT-TANGUY, Aline, MARJANOVIC, Zora, PARK, Sophie, RUBIO, Marie-Thérèse, MAROLLEAU, Jean-Pierre, GARNIER, Federico, FENAUX, Pierre, YAKOUB-AGHA, Ibrahim, BEGUIN, Yves, MICHALLET, Mauricette, MOHTY, Mohamad, VIGOUROUX, Stephane, BORIES, Pierre, GARNIER, Alice, EL CHEIKH, Jean

“…To investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell transplantation (alloSCT) for…”
Get full text

Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation by Boy, Maxime, Bisio, Valeria, Zhao, Lin-Pierre, Guidez, Fabien, Schell, Bérénice, Lereclus, Emilie, Henry, Guylaine, Villemonteix, Juliette, Rodrigues-Lima, Fernando, Gagne, Katia, Retiere, Christelle, Larcher, Lise, Kim, Rathana, Clappier, Emmanuelle, Sebert, Marie, Mekinian, Arsène, Fain, Olivier, Caignard, Anne, Espeli, Marion, Balabanian, Karl, Toubert, Antoine, Fenaux, Pierre, Ades, Lionel, Dulphy, Nicolas

“…Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders, representing high risk of progression to acute myeloid leukaemia, and frequently associated…”
Get full text

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial by Braun, Thorsten, Itzykson, Raphael, Renneville, Aline, de Renzis, Benoit, Dreyfus, François, Laribi, Kamel, Bouabdallah, Krimo, Vey, Norbert, Toma, Andrea, Recher, Christian, Royer, Bruno, Joly, Bertrand, Vekhoff, Anne, Lafon, Ingrid, Sanhes, Laurence, Meurice, Guillaume, Oréar, Cédric, Preudhomme, Claude, Gardin, Claude, Ades, Lionel, Fontenay, Michaela, Fenaux, Pierre, Droin, Nathalie, Solary, Eric

“…Hydroxyurea is the standard therapy of chronic myelomonocytic leukemia (CMML) presenting with advanced myeloproliferative and/or myelodysplastic features…”
Get full text

Empirical versus Preemptive Antifungal Therapy for High-Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial by Cordonnier, Catherine, Pautas, Cécile, Maury, Sébastien, Vekhoff, Anne, Farhat, Hassan, Suarez, Felipe, Dhédin, Nathalie, Isnard, Francoise, Ades, Lionel, Kuhnowski, Frédérique, Foulet, Françoise, Kuentz, Mathieu, Maison, Patrick, Bretagne, Stéphane, Schwarzinger, Michaël

“…Background. Empirical antifungal therapy is the standard of care for neutropenic patients with hematological malignancies who remain febrile despite…”
Get full text

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes by Zeidner, Joshua F, Mazerolle, Flora, Norton, Jonathan, Regnault, Antoine, Kristo, Fjoralba, Romero, Heather, Fram, Robert J, Faller, Douglas V, Dalal, Mehul, Ades, Lionel, Sekeres, Mikkael A

Get full text

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia by Lehmann-Che, Jacqueline, Bally, Cécile, Letouzé, Eric, Berthier, Caroline, Yuan, Hao, Jollivet, Florence, Ades, Lionel, Cassinat, Bruno, Hirsch, Pierre, Pigneux, Arnaud, Mozziconacci, Marie-Joelle, Kogan, Scott, Fenaux, Pierre, de Thé, Hugues

“…Retinoic acid (RA) and arsenic target the t(15;17)(q24;q21) PML/RARA driver of acute promyelocytic leukemia (APL), their combination now curing over 95%…”
Get full text

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia by Lengline, Etienne, Drenou, Bernard, Peterlin, Pierre, Tournilhac, Olivier, Abraham, Julie, Berceanu, Ana, Dupriez, Brigitte, Guillerm, Gaelle, Raffoux, Emmanuel, de Fontbrune, Flore Sicre, Ades, Lionel, Balsat, Marie, Chaoui, Driss, Coppo, Paul, Corm, Selim, Leblanc, Thierry, Maillard, Natacha, Terriou, Louis, Socié, Gerard, de Latour, Regis Peffault

“…Few therapeutic options are available for patients with aplastic anemia who are ineligible for transplantation or refractory to immunosuppressive therapy…”
Get full text

Exposure toxicity of venetoclax in acute myeloid leukemia patients in the real-life setting: impact of high exposure on delayed neutropenia by Puisset, Florent, Raffoux, Emmanuel, Ades, Lionel, Huynh, Tony, Itzykson, Raphaël, Bouscary, Didier, Aguinana, Loréa, Rabian, Florence, Sebert, Marie, Vekhoff, Anne, Brissot, Eolia, Mohty, Mohamad, Bonnin, Agnes, Genthon, Alexis, Zerbit, Jeremie, Willems, Lise, Decrocq, Justine, Contejean, Adrien, Lengline, Etienne, Mourah, Samia, Goldwirt, Lauriane

“…Not available.Not available…”
Get full text

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes by Cluzeau, Thomas, McGraw, Kathy L, Irvine, Brittany, Masala, Erico, Ades, Lionel, Basiorka, Ashley A, Maciejewski, Jaroslaw, Auberger, Patrick, Wei, Sheng, Fenaux, Pierre, Santini, Valeria, List, Alan

“…Accumulating evidence implicates innate immune activation in the pathobiology of myelodysplastic syndromes. A key myeloid-related inflammatory protein, S100A9,…”
Get full text

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients by Thépot, Sylvain, Itzykson, Raphael, Seegers, Valerie, Recher, Christian, Raffoux, Emmanuel, Quesnel, Bruno, Delaunay, Jacques, Cluzeau, Thomas, Marfaing Koka, Anne, Stamatoullas, Aspasia, Chaury, Marie‐Pierre, Dartigeas, Caroline, Cheze, Stéphane, Banos, Anne, Morel, Pierre, Plantier, Isabelle, Taksin, Anne‐Laure, Marolleau, Jean Pierre, Pautas, Cecile, Thomas, Xavier, Isnard, Francoise, Beve, Blandine, Chait, Yasmine, Guerci, Agnes, Vey, Norbert, Dreyfus, Francois, Ades, Lionel, Ifrah, Norbert, Dombret, Herve, Fenaux, Pierre, Gardin, Claude

“…Limited data are available on azacitidine (AZA) treatment and its prognostic factors in acute myeloid leukemia (AML). One hundred and forty‐nine previously…”
Get full text

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective by De Witte, Theo, Malcovati, Luca, Fenaux, Pierre, Bowen, David, Symeonidis, Argiris, Mittelman, Moshe, Stauder, Reinhard, Sanz, Guillermo, Čermák, Jaroslav, Langemeijer, Saskia, Hellström-Lindberg, Eva, Germing, Ulrich, Skov Holm, Mette, Mądry, Krzysztof, Tatic, Aurelia, Medina Almeida, António, Savic, Aleksandar, Mandac Rogulj, Inga, Itzykson, Raphael, Hoeks, Marlijn, Gravdahl Garelius, Hege, Culligan, Dominic, Kotsianidis, Ioannis, Ades, Lionel, Van de Loosdrecht, Arjan A, Van Marrewijk, Corine, Yu, Ge, Crouch, Simon, Smith, Alex

Get full text

Aging and blood disorders: new perspectives, new challenges by Bron, Dominique, Ades, Lionel, Fulop, Tamas, Goede, Valentin, Stauder, Reinhard

Get full text

A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM) by Ades, Lionel, Guerci-Bresler, Agnès, Cony-Makhoul, Pascale, Legros, Laurence, Sebert, Marie, Braun, Thorsten, Delaunay, Jacques, Desseaux, Kristell, Chevret, Sylvie, Fenaux, Pierre

Get full text

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia by Maslah, Nabih, Salomao, Norman, Drevon, Louis, Verger, Emmanuelle, Partouche, Nicolas, Ly, Pierre, Aubin, Philippe, Naoui, Nadia, Schlageter, Marie-Helene, Bally, Cecile, Miekoutima, Elsa, Rahmé, Ramy, Lehmann-Che, Jacqueline, Ades, Lionel, Fenaux, Pierre, Cassinat, Bruno, Giraudier, Stephane

“…Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival…”
Get full text

How we treat lower-risk myelodysplastic syndromes by Fenaux, Pierre, Adès, Lionel

“…Lower-risk myelodysplastic syndromes (MDSs) are defined as having low or intermediate 1 risk by the International Prognostic Scoring System and are…”
Get full text

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial) by Rahmé, Ramy, Ades, Lionel, Thomas, Xavier, Guerci-Bresler, Agnès, Pigneux, Arnaud, Vey, Norbert, Raffoux, Emmanuel, Castaigne, Sylvie, Spertini, Olivier, Wittnebel, Sebastian, Marolleau, Jean Pierre, Damaj, Gandhi, Bordessoule, Dominique, Lejeune, Julie, Chevret, Sylvie, Fenaux, Pierre

Get full text

Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features by Wechalekar, Mihir D., Zhao, Lin-Pierre, Kutyna, Monika M., Hong, Lih En, Li, Joule, Hung, Kevin, Scott, Hamish S., Brown, Anna, Hahn, Christopher C., Kassahn, Karin, Ladon, Dariusz, Yeung, David T., Thomas, Daniel, Patnaik, Mrinal, Proudman, Susanna, Ades, Lionel, Shah, Mithun V., Kok, Chung H., Hiwase, Devendra K.

Get full text